Hospitalized Children Clinical Trial
— ORIGAMIOfficial title:
National Observatory of Mycoplasma Infections in Hospitalized Children Under 18 Ages in France
This study was set up because of an unusual increase in the number of cases of mycoplasma infections in France between June and November 2023. Clinical data from children with mycoplasma infections will be collected to characterise this infection and facilitate hospital management.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | September 1, 2030 |
Est. primary completion date | September 1, 2030 |
Accepts healthy volunteers | |
Gender | All |
Age group | 1 Day to 17 Years |
Eligibility | Inclusion Criteria: - Age <18 years (only hospitalized children) - Documented mycoplasma infection (positive multiplex PCR and/or positive serology) Exclusion Criteria: - Refusal by one of the parents or by Child in understanding age |
Country | Name | City | State |
---|---|---|---|
France | ACTIV | Créteil |
Lead Sponsor | Collaborator |
---|---|
Association Clinique Thérapeutique Infantile du val de Marne | GPIP |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients hospitalized for mycoplasma infections | Proportion of hospitalized children due to mycoplasma infections | 1 year | |
Primary | medical characterisation of mycoplasma infections | Assessment of clinical, biological and microbiological characteristics of mycoplasma infections cases. | 1 year | |
Secondary | Identify risk factors of serious infection | Describe what is responsible of serious infection. | 1 year | |
Secondary | Identify predictive signs of serious infection | what are the warning signs of a serious infection? | 1 year | |
Secondary | Type of complications | Describe any complications due to infection | 1 year | |
Secondary | Patients outcome | Proportion of patients recovered | 1 year | |
Secondary | healthcare used for infected children | Describe healthcare provided during hospitalisation of infected children in order to manage this type of infection | 1 year | |
Secondary | treatment used during hospitalisation | type of treatment used during hospitalisation to manage the infection | 1 year | |
Secondary | clinical description of infected children | clinical description of all cases of mycoplasma infections reported during the study | 1 year | |
Secondary | Type of mycoplasma involved in infected children | characterisation of mycoplasma involved in infection (strain, molecular epidemiology and antibiotic resistance) | 1 year | |
Secondary | performance of complementary diagnostic tests for lung disorders | for lung disorders, assessment of performance of complementary diagnostic tests (chest X-ray, lung ultrasound, C reactive protein (CRP), multiplex polymerase chain reaction (PCR), etc). | 1 year | |
Secondary | compare medical data collected during hospitalisation | Assessment of the correlation between clinical, radiological and biological data of infected children | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04377568 -
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
|
Phase 2 | |
Completed |
NCT02852590 -
Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children
|
N/A | |
Completed |
NCT03586180 -
Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
|
||
Recruiting |
NCT05551156 -
The Role of Therapy Dogs in Reducing Depression, Anxiety, and Loneliness Among Hospitalized Children
|
N/A | |
Recruiting |
NCT06260345 -
CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit
|
||
Completed |
NCT03599674 -
Targeted Inpatient Navigation to Improve Care for Minority Children and Families
|
N/A |